Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Kaposi 1Lymphoma 1HIV Infections 1Acquired Immunodeficiency Syndrome 1

Interventions

Doxorubicin 8Vincristine 7Etoposide 7Cyclophosphamide 7Rituximab 5Prednisone 5Filgrastim 5Zidovudine 3Bleomycin 3Vinblastine 2Thalidomide 2Paclitaxel 2Mitoxantrone 2Interferon-alpha 2Interferon alpha-2 2Dacarbazine 2Cytarabine 2Cisplatin 2ziconotide 1vesnarinone 1tin etiopurpurin 1nirogacestat 1liposomal doxorubicin 1interferon gamma-1b 1fludarabine phosphate 1fludarabine 1efavirenz 1dehydroftorafur 1Whole-Body Irradiation 1Valganciclovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × HIV Infections × Didanosine × Clear all
NCT00001114 2021-11-01

The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Completed
90 enrolled
Sarcoma

Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡